LIVE LONGER
Imagine this: a world where cancer is caught early enough to be effectively treated without the need for debilitating surgery or destructive chemotherapy. A world where we do not have to suffer the loss of loved ones who leave us too early. Thanks to Al’s power and genetic sequencing advances, Renovaro is taking the lead in making this vision a reality by combining advanced diagnostic and personalized immunotherapy.
NEWS
Our Story
Renovaro Inc.
Renovaro is driven by an unwavering commitment to revolutionize healthcare. Our primary objectives encompass pioneering advancements in AI, diagnostics and therapies for patients with cancer.
RenovaroCube
Renovaro Cube is commited to use liquid biopsies for the full patient journey.
RenovaroBio
RenovaroBio has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
From Strength to Strength
Both RenovaroCube and RenovaroBio are at the forefront of oncology innovations, revolutionizing the field of cancer treatment. RenovaroBio is committed to a future where survival is increased the toxic effects of chemotherapy are eliminated. They are focused on developing next-generation diagnostics and immunotherapy, specifically dendritic cell-based therapy, as an alternative to chemotherapy.
RenovaroCube is dedicated to develop the next generation of diagnostics for early detection of the disease, treatment selection, response prediction and follow-up of disease spanning the full patient journey using only one simple vial of blood (liquid biopsies). Collectively we offer a holistic approach to cancer treatment, benefiting not only patients but also clinicians and healthcare providers by employing a vertically integrated approach.
Our mission
Integrating the power of AI from diagnosis through treatment and recovery
Our Goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
- To impact patients from diagnostics through theraputic intervention
- A future free from toxic Chemotherapy
- Detection of diseases before the appearance of symptoms
- Non-invasive liquid biopsy testing
Our Team
COMMITTED TO RADICALLY ACCELERATE PRECISION MEDICINE
Maurice van Tilburg – Glimne
Chairman
David Weinstein
Director & Chief Executive Officer (CEO)
Douglas W. Calder
Director
Mark Collins, Phd
Director
James A. McNulty
Director
Simon Tarsh
Interim Chief Financial Officer (CFO)
